



GTCTCTTACC CCGATGTTCA ACCAAAAG ACTTACTACC TTTATTTTAT GTTTACTTTT TATAGATTGT CTTTTTATC  
CTCTCTTACC CCGATGTTCA ACCAAAAG ACTTACTACC TTTATTTTAT GTTTACTTTT TATAGATTGT CTTTTTATC  
CTCTCTTACC CCGATGTTCA ACCAAAAG ACTTACTACC TTTATTTTAT GTTTACTTTT TATAGATTGT CTTTTTATC

## HUMAN INTERFERON ALPHA WA

Product Number: 11190-1

Lot Number:

Size:  $\geq 1 \times 10^5$  units

**Description:** Recombinant Human Interferon Alpha WA (Hu-IFN- $\alpha$ WA; Hu-IFN- $\alpha$ 16)

**Volume:** 0.1 ml

**Activity:** x 10 units/ml (MDBK/VSV)

**Specific Activity:** x 10 units/mg (MDBK/VSV)

**Buffer:** phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA)

**Endotoxin:** EU/ $\mu$ g

**Molecular Weight:** 19.3 kDa

**Purity:**  $\geq 95\%$

**Purification Method:** Purified from E. coli by a combination of Ion Exchange and size exclusion chromatography

**Source:** cDNA obtained from human leukocyte mRNA expressed in E. coli

**Human Gene:** IFNA16

**Synonyms:** Hu-IFN- $\alpha$ 16

**Accession Number:** X02957

**Assay Used to Measure Bioactivity:** Interferon was titrated with the use of the cytopathic effect inhibition assay as listed.

*Bovine (MDBK/VSV)* - performed as described [Rubinstein *et al.* (1981) *J. Virol.* 37(2):755] The EC<sub>50</sub> for interferon in this assay is ~5 U/ml. Lot Activity was derived from multiple determinations in the above assay.

*Human (A549/EMCV)* - performed as described [Budd *et al.* (1985) *Canc. Chem. Pharm.* 12:39]. The EC<sub>50</sub> for interferon in this assay is ~1 U/ml. **Activity:** x 10 units/ml **Specific Activity:** x 10 units/mg

The units are determined by use of a Human IFN Alpha A [Hu IFN- $\alpha$ A [2a]] laboratory standard calibrated to the international reference standard for Human Interferon Alpha A [Hu IFN- $\alpha$ A [2a]] provided by the National Institutes of Health [Meager *et al.* (2001) *J. Immunol Methods.* 257(1-2):17-33]. Please note that IFN assays vary between labs and assay systems [Meager *et al.* (2001) *J. Immunol. Meth.* 257:17. Meager and Das (2005) *J. Immunol. Meth.* 306:1]

### Shipping Information

**Shipping Conditions:** Dry ice

**Physical State of Product during Shipping:** Frozen

**Special Conditions/Comments:** After receipt, this product should be kept at -70°C or below for retention of full activity. When thawing, the contents of the tube should be apportioned in separate tubes so that freezing and thawing is kept to a minimum. Re-freezing should be done on dry ice or in a dry ice/alcohol bath. Further dilution of the product should be in buffers containing protein such as 0.1% bovine serum albumin (BSA) or Tissue Culture Media with serum. Dilution for freezing of material below  $2 \times 10^5$  units/ml is not recommended. One freeze-thaw cycle is equivalent to thawing an aliquot prepared from the material received. [The activity measured after one freeze-thaw cycle is x 10 units/ml (MDBK/VSV)].

### Authorization

Released by: \_\_\_\_\_

Date:

Sold under license from Pestka Biomedical Laboratories, Inc. d/b/a PBL InterferonSource. For research use only. Not for diagnostic or clinical use in, or administration to, humans. Not for resale in original or any modified form, including inclusion in a kit, for any purpose. Not for use in the preparation of any commercial product.

Rev.02

131 Ethel Rd West, Suite 6, Piscataway, NJ 08854 • T: +1-732-777-9123 • F: +1-732-777-9141

E: info@interferonsource.com • W: www.interferonsource.com